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Mycobacterium tuberculosis and M. bovis share >99% genetic identity and induce similar host responses and disease profiles
upon infection. There is a rich history of codiscovery in the development of control measures applicable to both human and
bovine tuberculosis (TB) including skin-testing procedures, M. bovis BCG vaccination, and interferon-γ release assays. The calf
TB infection model oﬀers several opportunities to further our understanding of TB immunopathogenesis. Recent observations
include correlation of central memory immune responses with TB vaccine eﬃcacy, association of SIRPα+ cells in ESAT-6:CFP10-
elicited multinucleate giant cell formation, early γδ T cell responses to TB, antimycobacterial activity of memory CD4+ T cells via
granulysin production, association of specific antibody with antigen burden, and suppression of innate immune gene expression
in infected animals. Partnerships teaming researchers with veterinary and medical perspectives will continue to provide mutual
benefit to TB research in man and animals.
1. Introduction: History of Codiscovery
Three essential tools developed in cattle and used for the con-
trol of human tuberculosis (TB) include (1) vaccination with
an attenuated Mycobacterium bovis Bacillus Calmette Guerin
(BCG, [1]), (2) use of tuberculin as an in vivo diagnostic
reagent, and (3) antigen-induced interferon- (IFN-) γ as an
in vitro biomarker of TB infection. In 1913 at the Pasteur
Institute (Lille, France), Albert Calmette and Camille Guerin
vaccinated 9 cows with M. bovis (Nocard strain) attenuated
by serial passage on glycerol-soaked potato slices in ox bile
(i.e., BCG) [1]. All 9 animals were protected from challenge
with virulent M. bovis, thereby, demonstrating the potential
use of BCG vaccination against M. tuberculosis infection
of humans. In 1921, BCG was administered to a newborn
child (6mg orally) and has since been used widely for the
control of human TB. Within a few years of the discovery
of tuberculin by Robert Koch, veterinary investigators in
Russia (Professor Gutman), the UK (John McFadyean),
Denmark (Bernhard Bang), and the US (Leonard Pearson
and Maz’yck Ravenel) were administering tuberculin to
cattle as an in vivo diagnostic reagent (infection indicated
by a rise in temperature within 24 hours) [2]. Clemens
von Pirquet and Charles Mantoux later (circa 1907/1908)
adapted and improved (e.g., subcutaneous to intradermal)
this technology for application in the diagnosis of TB in
humans, coincidently defining the principles of allergy and
delayed type hypersensitivity. During the 1980s, an in vitro
IFN-γ release assay was developed for the diagnosis of
TB in cattle [3]; a modified version of this assay is now
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widely used in the diagnosis of both human and bovine TB.
Together, these findings demonstrate the mutual benefit for
cooperative veterinary and medical research. As stated by
Emil von Behring in his Nobel Prize acceptance speech [4],
“I need hardly add that the fight against cattle tuberculosis
only marks a stage on the road which leads finally to the
eﬀective protection of human beings against the disease.” The
current review highlights recent observations on immunity
to bovine TB of relevance for understanding the disease, both
in cattle and humans.
2. The Neonatal Calf as a Model for
the Study of TB
2.1. Mycobacterium bovis. Mycobacterium bovis, a member
of the M. tuberculosis complex, has a wide host range
as compared to other species in this disease complex,
is infectious to humans, and is the species most often
isolated from tuberculous cattle. Prior to implementation
of widescale pasteurization, it is estimated that 20–40% of
TB cases in humans resulted from infection with M. bovis
[5–7]. An explanation, not apparent at the time, suggests a
diﬀerence in the capacity of M. tuberculosis and M. bovis to
infect and cause disease in cattle. Genome comparisons show
that M. bovis and M. tuberculosis evolved into two clades
from a common prototypic ancestor some 40,000 years ago:
clades defined by presence or absence of M. tuberculosis
deletion 1 (TbD1) [8]. The data suggest that both clades
arose in humans, with the TbD1− clade 1 coevolving mainly
in humans and the TbD1+ clade 2 coevolving in humans,
ruminants, and other species. The diﬀerence in host range
shows that evolution of M. bovis and M. tuberculosis has
included development of a diﬀerence in virulence and
the capacity to cause disease in diﬀerent species. This
diﬀerence may prove useful in comparative studies designed
to elucidate the mechanisms of immunopathogenesis and
development of vaccines. Approximately 90% of humans
exposed to M. tuberculosis develop an immune response
that controls but does not eliminate the pathogen. Immune
control of this persistent (latent) stage of infection may
persist for a lifetime or become dysregulated, allowing for
disease progression. It is not clear whether a comparable
proportion of humans infected with M. bovis develop an
immune response that controls infection. Recent direct
comparison of M. bovis and M. tuberculosis infection in
cattle has demonstrated that M. tuberculosis is less virulent
for cattle; however, the M. tuberculosis strain used for
these studies was a laboratory-adapted strain (H37Rv) [9].
However, experimental transmission studies (conducted in
the late 1800s by Theobald Smith (physician scientist) and
veterinarians Austin Peters and Langdon Frothingham using
calves experimentally inoculated with sputum from humans
with tuberculosis), demonstrated that human bacilli possess
a low virulence for cattle [10]. Other studies clearly demon-
strated that nonlaboratory-adapted strains of M. tuberculosis
were less virulent in cattle than those of M. bovis (reviewed
by Whelan et al., 2010 [9]). Analysis of the diﬀerence in the
immune response to the two pathogens may provide insight
into the mechanisms used by both bacteria to circumvent
protective immunity [11].
2.2. Aerosol Infection Model. Aerosol inoculation of M. bovis
to calves results in a respiratory tract infection (i.e., lungs and
lung-associated lymph nodes), severity is dose-dependent,
and the disease closelymimics natural infection of cattle [12].
As related to human disease, studies with neonatal calves are
particularly relevant as this is the primary target population
for human vaccination and exposure to TB often occurs
at a very young age. For calf vaccine studies, parameters
to demonstrate eﬃcacy include quantitative and qualitative
mycobacterial culture, gross andmicroscopic disease scoring,
radiographic morphometry of lung lesions, and disease-
associated immune parameters. Opportunities aﬀorded by
use of the calf model include (1) large numbers of aﬀordable
age-, gender-, and breed-matched animals available through-
out the year (nonhuman primates (NHPs) are seasonal
breeders and are costly), (2) cattle are out-bred species,
thus, experimental variance is similar to what is expected
for NHP and humans, (3) size allows dose titration studies
and full immunologic assessment via frequent collection of
large volumes of blood which facilitates studies on immune
response kinetics, (4) the nutritional status (e.g., vitamin
deficiencies and protein malnutrition) can be manipulated
to achieve similar levels of deficiency as may occur in target
human populations in the developing world, (5) serves
as an additional safety screen for evaluation of vaccines,
adjuvants, or other administered biologics, and (6) feasibility
of duration of immunity studies.
2.3. Parallel Testing of Vaccine Candidates in the Primate and
Calf Model-mc26030. A double deletion mutant of M. tuber-
culosis H37Rv (i.e., ΔRD1-the primary attenuating mutation
of BCG and ΔpanCD-deletion of pantothenate synthesis
genes) was evaluated in parallel with BCG (Copenhagen
strain) in both the calf model and adolescent Cynomologus
monkeys (Macaca fascicularis). The M. tuberculosis ΔRD1
X panCD mutant (mc26030) undergoes limited replication
in mice and is safer than BCG in immunocompromised
mice (i.e., SCID, IFN-γ receptor-deficient and CD4-deficient
mice) [13]. Immunization with this mutant strain of H37Rv
induces prolonged protective immune responses that pro-
mote survival of both wild type and CD4-deficient mice
against an aerosol challenge with virulent M. tuberculosis.
Antibody depletion and adoptive transfer studies revealed
that protection in CD4-deficient mice was mediated in the
absence of CD4+, CD8+, γδ+, and NK1.1+ T cells, thus,
indicating a surprising capacity for protection to be elicited
by CD4−CD8− TCR−αβ+ cells [14]. For second tier testing,
mc26030 was evaluated for eﬃcacy in the newborn calf
model and adolescent Cynomologus monkeys. In both calves
and monkeys, the vaccine was ineﬀective [15, 16]; thus,
in this instance, responses in mice were not predictive of
eﬃcacy in models using natural hosts of infection. For cattle,
attenuatedM. tuberculosismutants may be less immunogenic
as compared to those produced on a virulent M. bovis
or BCG strain; thus, cattle may not be as useful as other
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models (e.g., monkeys) for the study of vaccine eﬃcacy
using M. tuberculosis mutants. Further studies are required
to directly compare immunogenicity and virulence of M.
tuberculosis versus M. bovis background mutants in cattle.
3. Bovine DCs and Macrophages
The role of signal regulatory protein alpha-expressing (SIRPα+)
cells in the adaptive response to tuberculous mycobacteria
via interactions with ESAT-6/CFP-10. Multiple functions are
proposed for the RD1 proteins ESAT-6 and CFP-10 [17, 18].
For instance, ESAT-6 interacts with biomembranes after
dissociation from its putative CFP-10 chaperone within the
acidic phagolysosome [19], thereby aﬀording a “phagolyso-
some escape” mechanism for the pathogen. ESAT-6 deletion
mutants of M. tuberculosis have reduced tissue invasiveness,
likely due to loss of cytolytic activity [20]. In addition, use of
the M. marinum/zebrafish granuloma model demonstrates
that RD1 components are required for eﬃcient recruitment
of macrophages to granulomas “creating new bacterial
growth niches” [21, 22]. RD-1 proteins, including ESAT-
6/CFP-10, likely elicit more rapid granuloma formation
oﬀering a distinct growth advantage for the pathogen [22].
In addition to enhancing recruitment of cells susceptible to
infection, the stable ESAT-6/CFP-10 complex binds to host
cells [23]; thereby, modulating the host response favourably
for the pathogen via down-regulation of host cell killing
mechanisms and immune cell activation [24].
A specific receptor (TLR2) for ESAT-6 has been identified
using mouse monocyte/macrophage cell lines [25]. Studies
with leukocytes obtained from cattle have also demon-
strated a specific interaction of the ESAT-6/CFP-10 complex
with CD172a (SIRPα)-expressing cells [26]. Stimulation of
peripheral blood mononuclear cell cultures from M. bovis-
infected calves with ESAT-6/CFP-10 results in the specific
expansion of SIRPα+ cells, with binding of the fusion protein
bound to the surface of SIRPα+ cells [26]. SIRPα-CD47
interactions are essential for eﬃcient migration of DCs to
skin [27] and secondary lymphoid organs [28]. Thus, ESAT-
6/CFP-10-induced expansion of SIRPα-expressing cells may
favour migration of DC’s/macrophages to infection sites,
thereby, promoting eﬃcient granuloma formation and early
dissemination of M. tuberculosis complex mycobacteria [22].
With the bovine TB model, intradermal injection of rESAT-
6:CFP-10 elicits granuloma formation with infiltration of
numerous T cells, SIRPα+ cells, and CD14+ cells in M. bovis-
infected calves, further supporting a role for ESAT-6/CFP-
10 in the recruitment of naı¨ve cells to sites of granuloma
formation [26]. A unique aspect of the cellular infiltrates
at rESAT-6:CFP-10 injection sites in cattle is the presence
of numerous multinucleated giant cells. Multinucleated
giant cell formation is mediated, in part, by SIRPα (also
termed macrophage fusion receptor). Cell surface expression
of SIRPα is strongly and transiently induced upon giant
cell formation. As opposed to phagocytosis, SIRPα-CD47
interactions provide “self recognition” signals that prevent
killing of internalized (i.e., fused) cells. Thus, cattle may
serve as a useful model for the molecular characterization of
multinucleate giant cell formation within tuberculous gran-
ulomas. Additionally, comparative studies examining ESAT-
6/CFP-10 interactions with SIRPα and TLR2 in mouse,
human, and bovine tissues are needed to determine if host
factors aﬀect ESAT-6/CFP-10 specificity.
4. T Cell Subsets and Effector Mechanisms
4.1. Cell-Mediated Immunity (CMI). Ongoing studies have
shown the adaptive immune system of cattle is quite similar
to the human system [29]. Importantly, comparisons at
the genomic level indicate that genes encoding cytokines
known to play a role in regulating immune responses
in humans are present in cattle, including cytokines not
found in mice (e.g., IL-26). Cell-mediated immunity is
essential for protection against bovine and human TB and
there appears to be significant similarity in the primary
mechanisms of antimycobacterial CMI between humans
(as reviewed in [30]) and cattle (as reviewed in [31]).
Similarities include roles of T cell subsets (e.g., CD4+, CD8+,
and γδ TCR+), protective function and cellular sources
of IFNγ and cytotoxic granule proteins; the reduction of
mycobacterial numbers within macrophages by cytotoxic
T cells and NK cells, the relative levels of antigen specific
Th1 and Th2 cytokines, and expression of memory markers
by antigen specific T cells [32–42]. Widely utilized for TB
diagnosis, antigen-specific release of IFN-γ is clearly an
important function of the CMI response to TB in cattle
and humans [43, 44]. In contrast to rodents, human and
bovine immunity to TB appears to be less reliant on
antigen-specific IFN-γ activation of macrophages [45, 46]
and may employ cytotoxic immune cells in a more active
role.
Protective immunity to TB in cattle, as in human and
other animal models of TB, correlates to the induction of
Type 1 T cell cytokines following antigen specific stim-
ulation [45, 47]. The balance of cytokines (IFN-γ, IL-4)
elicited by mycobacterial antigens in bovine T cells, however,
is more similar to cytokine profiles observed following
immunization of humans than of mice. Relative levels
of IFN-γ and IL-4 expressed by lymph node T cells
correlate to tissue pathology and bacterial load in vacci-
nation/challenge studies of bovine TB [15, 48]. In BCG-
vaccinated neonatal calves, antigen-specific expression of
IL-2 and IFN-γ by peripheral blood leukocytes correlated
with clinical protection following challenge with virulent
M. bovis [48]. A potential role for the Th2/Th17 cytokine
IL-21 in protection against mycobacterial disease was
recently identified for the first time in a calf model of TB
[35]. IL-21 is a member of the common gamma chain family
of cytokines (IL-2, IL-7, IL-15) and is secreted primarily
by CD4+ T cells [49]. Following vaccination with BCG,
CD4+ T cells from immunized cattle expressed IL-21 upon
in vitro stimulation with PPD [35]. Expression of IL-21 in
these studies correlated with cytotoxic activity and eﬀector
molecule expression by antigen-stimulated CD4+ T cells and
occurred late in the antigen-specific response, similar to
perforin. The role of IL-21 and other key regulatory factors
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for maintenance and induction of IFN-γ (IL-12, IL-18,
IL-23, and IL-27) and NK cell function in protective
immunity to TB is an important avenue of investigation in
the eﬀorts to develop a vaccine for humans and cattle.
4.2. γδ T Cells in Bovine Tuberculosis. γδ T cells may form
a key component linking innate and adaptive responses to
M. bovis infection in cattle given their active release of IFN-γ
and relatively high prevalence in the blood of young calves
as compared to adults [50]. There are two phenotypically
distinct subsets of γδ T cells in cattle, workshop cluster
1 (WC1)+ CD2− and WC1− CD2+γδ T cells. Unique to
Artiodactyla, WC1 is a member of the scavenger cysteine rich
gene family that includes CD5 and CD6 [51]. Diﬀerences in
abundance, tissue distribution, patterns of circulation, and
TCR gene usage suggest that the two major γδ T cell subsets
(WC1+ and WC1−) play diﬀerent roles in host defense
[52–55]. Orthologues of WC1 have only been identified in
pigs and camelids [51, 56–59] but there is no known ortho-
logue ofWC1 in primates. Isoforms ofWC1 are encoded by a
cluster of thirteen genes distributed between two loci in cattle
[51, 56–58] and studies have demonstrated that multiple
gene products from the two loci are coexpressed forming two
essentially mutually exclusive populations with an apparent
dichotomy in function [60, 61]. These two subsets—referred
to as WC1.1+ and WC1.2+—are defined by diﬀerential
staining with specific monoclonal antibodies. Functional
studies have demonstrated that the subset expressing WC1.1
is a major source of IFN-γ following antigenic stimulation
[55] and is likely an early source of perforin and granulysin.
The relative proportions of WC1.1+and WC1.2+cells change
with age, with a predominance of WC1.1+γδ T cells in young
cattle [62]. In addition, we showed that WC1+γδ T cells
from young cattle had a greater capacity for IFNγ secretion,
compared to WC1+γδ T cells from adult cattle, and that this
was due to a higher number of WC1.1+ cells in the young
calves [63].
γδ T cells respond to mycobacterial antigens including
crude and defined antigens, heat shock proteins, and other
nonproteinaceous components which may be expressed rela-
tively early in infection with M. bovis or other mycobacterial
species [64–66]. The eﬀector contribution of the WC1+γδ T
cells to M. bovis immunity in cattle is not fully elucidated but
early roles postinfection and postvaccination are indicated
from a number of studies in cattle and in mice. Vaccination
of calves with BCG induced an early increase in circulating
WC1+γδ T cells which was associated with an increase in
the secretion of antigen-specific IFN-γ [67]. We also showed
that intranasal administration of BCG induced significant
increases in WC1.1+ T cells in the lungs of immunised
calves and that these cells clustered with DC in tissues
[50]. In M. bovis-infected cattle, WC1+γδ T cells were
detected within lesions early in the course of infection
[68, 69]. Concurrently, numbers of circulating WC1+γδ T
cells decrease shortly after infection, followed by a rapid
increase [66]. In vivo depletion ofWC1+γδ T cells from cattle
prior to infection did not alter the course of disease [70]
but, rather, significantly influenced the immune bias of the
antigen-specific response. These data suggest thatWC1+ cells
may be involved in directing immune bias through IFN-γ
secretion, as theWC1+γδ T cell-depleted cattle had increased
IL-4 expression and altered immunoglobulin isotype profile
as compared to nondepleted, M. bovis-infected controls
[70]. Studies in mice have also revealed roles for γδ T
cells in immune responses to Mycobacteria spp.. The WC1-
bearing γδ T-cell population was shown to have an essential
role in regulating inflammation in both the liver and the
spleen of M. bovis-infected SCID-bovine heterochimeric
(mouse-bovine) chimeras [37]. A similar regulatory eﬀect
of γδ T lymphocytes in inflammatory responses induced
by M. tuberculosis was also reported to influence bacterial
survival within tissues [71]. The early presence of γδ
T cells in tuberculous lesions likely promotes containment of
M. bovis via cytokine (e.g., IL-12 and IFN-γ), granulysin, and
chemokine release stimulating macrophage activation and T
cell recruitment [70, 72, 73]. However, recent studies in the
SCID-bovine heterochimeric mouse model have shown that
γδ T cells are not a primary source of chemokines in response
to various agonists but may influence other cells types
(including macrophages) in the production of chemokines
and granuloma formation [74]. Treatment of mice with
an anti-WC1 monoclonal antibody resulted in an apparent
loss of control of the inflammatory response confirming
important roles for WC1+γδ T cells in vivo in regulation
of the immune response. Similar findings were obtained
with mycobacterial infection of γδ TCR knockout mice
[75, 76]. Interestingly other studies have also shown that it
is the bovine WC1.1+ and WC1.2+γδ T cells which act as
T regulatory cells, not CD4+CD25+FoxP3+ cells as has been
observed in other species [77]. The available data suggest
that bovine WC1+γδ T cells have multiple roles and can be
both regulatory and stimulatory through the expression of
cytokines. Their exact roles in M. bovis immunity remain to
be fully revealed.
4.3. Cytotoxic Lymphocytes (CTLs) and Biomarkers for
Eﬀector Mechanisms in Bovine TB. Human and murine
CD4+, CD8+, and γδ T cells exhibit CTL activity against
mycobacterial-infected targets, indicating a role in immunity
to TB [78–81]. Production of granulysin by CTL reduces
intracellular mycobacteria and appears to require perforin
to gain access to the interior of the infected cell. Bovine
T cells express a homologue of human granulysin, a potent
antimicrobial protein stored with perforin in cytotoxic
granules [34]. Memory CD4+ T cells (CD45R0+) from BCG-
vaccinated animals are eﬃcient at reducing colony forming
units of BCG in infected macrophages following antigen
specific stimulation [35]. This antimycobacterial activity
correlates with expression of perforin, granulysin, and IFN-γ
by the same memory subset. Expression of the bovine
granulysin gene can be induced in CD4+, CD8+, and γδ T
cells resulting in antimycobacterial activity similar to human
granulysin [34, 35]. Using laser capture microdissection,
granulysin mRNA was detected in the lymphocytic cuﬀ of
a forming granuloma, simultaneous with M. bovis DNA,
in an experimentally challenged calf [34]. Granulysin and
perforin gene expression are upregulated in peripheral blood
CD4+ and CD8+ T cells in both BCG- and M. bovis
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ΔRD1-vaccinated calves (protected) as compared with non-
vaccinated (not protected) calves [82], demonstrating the
potential of these biomarkers as correlates of protection
for prioritizing vaccine candidates. To date, a murine and
guinea pig orthologue of granulysin has not been identified,
precluding studies of the full repertoire of lytic granule
proteins in rodent models of TB. Further studies of pro-
tective biomarkers in peripheral blood and granulomas of
vaccinated and experimentally infected cattle have significant
potential for testing strategies for augmenting immunity by
vaccination.
Bovine NK cells have been identified with a mAb
specific for CD335 [83, 84] and numbers of NK cells in
peripheral blood were found to be highest in young calves
[83, 85]. The population is comprised of CD2+ and CD2−
subsets expressing combinations of killer immunoglobulin-
like receptors (KIRs), leukocyte-receptor complex (LRC)
CD94/NKG2C (inhibitory) and CD94/NKG2A (activating),
NKG2D, and lectin-like receptors Ly49, CD69, NKP-R1,
and KLRJ (reviewed in [86]). Initial studies suggest that
NK cells play a significant role in the innate response to
mycobacterial pathogens [33, 87–89]. They are an initial
source of IFN-γ, IL-17, and IL-22 that play a role in the
inflammatory response to intracellular pathogens, including
M. tuberculosis, and a source of perforin and granulysin.
Bovine neonatal NK cells were shown to be a major source of
IFNγ through interactions with BCG-infected DCs and this
may be a pivotal early influence in vivo [88].
NKT cells have not been identified in cattle. Analysis of
the CD1 family of proteins involved in antigen presentation
to NK and NKT cells suggests NKT cells may not be present
in cattle or that receptor usage diﬀers markedly from that in
humans and mice. The CD1 family in cattle is comprised of
genes encoding CD1a, multiple CD1b molecules, and CD1e.
An orthologue of the human CD1c gene is not present in the
bovine genome. Both identified CD1d genes are pseudogenes
supporting the possibility that NKT cells may be absent [90].
5. Immunological Parameters as Correlates of
Protection versus Indicators of Disease
5.1. T Cell Central Memory (TcM) Immune Responses.
Costly and protracted eﬃcacy studies using various and
often multiple animal models are currently used to eval-
uate human TB vaccine candidates [91]. Vaccine-elicited
immune parameters (i.e., correlates of protection) are very
much needed to prioritize the multitude of candidates.
Several vaccine studies with cattle have demonstrated that
TcM responses [92] negatively correlate with mycobacterial
burden [93] and TB-associated pathology [94]; thus, TcM
responses are positive correlates of protection. With the
TcM assay, short-term T cell lines are generated via stim-
ulation of peripheral blood mononuclear cells with specific
antigens including Ag85A/TB10.4 and M. bovis PPD. Early
eﬀector T cell responses wane over time and memory cells
are maintained via addition of IL-2 and fresh medium.
On the final day of culture (∼13d), cells are moved to
plates containing autologous antigen presenting cells and
antigen for elicitation of TcM responses as measured by
IFN-γ ELISPOT.With two independent vaccine eﬃcacy trials
[93, 94], protected calves had greater TcM responses as com-
pared to nonprotected calves. As with TcM responses, IL-17
responses (as measured by real time RT-PCR) also correlated
with protection [94]. Recent findings indicate that IL-21 and
IL-22 may also be good candidates for further evaluation
(Davis and Waters, unpublished observations). These data
demonstrate the potential for defining a protective signature
elicited by vaccination to prioritize candidates for eﬃcacy
testing within calves.
5.2. Immune Activation as a Positive Indicator of Disease
andNegative Indicator of Vaccine Eﬃcacy. Positive prognostic
indicators (i.e., as measured after challenge) for vaccine
eﬃcacy include reduced antigen-specific IFN-γ, iNOS,
IL-4, and MIP1-α (CCL3) responses, reduced expansion of
CD4+ cells in culture, and a diminished activation profile
(i.e, ↓ expression of CD25 and CD44 and ↑ expression of
CD62L) on T cells with antigen-stimulated cultures [15].
In particular, reduced responses to ESAT-6/CFP-10 upon
experimental challenge are positive prognostic indicators for
vaccine eﬃcacy [44, 93, 95] whereas robust or increasing
cellular immune responses (with the exception of IL-17
[94]) to ESAT-6/CFP-10 are generally a negative prognostic
indicator of vaccine eﬃcacy. These findings are consistent
with the diagnostic capacity for ESAT-6/CFP-10 as antigens
in cellular immune assays. Prognostic indicators oﬀer ante-
mortem monitoring techniques for vaccine eﬃcacy studies.
5.3. Association of Antibody Responses to Antigen Burden.
Antibody responses generally correlate to mycobacterial-
elicited pathology [96] in accordance with the belief that
Mycobacteria spp. induce antibody primarily late in the
course of infection. To further evaluate the correlation
of antibody responses to disease expression, calves were
inoculated with M. bovis, M. kansasii, or M. tuberculosis
and immune responses evaluated [9, 11]. Disease expres-
sion ranged from mycobacterial colonization with associ-
ated pathology (M. bovis), colonization without pathol-
ogy (M. tuberculosis), to no colonization or pathology
(M. kansasii). Antibody responses were associated with
antigen burden; cellular responses (i.e., to PPD) correlated
with infection but not necessarily with pathology or bacterial
burden; exposure to mycobacterial antigens (in this case,
injection of PPD for skin test) boosted antibody responses in
presensitized animals. Thus, evaluation of antibody response
to mycobacterial infections may be useful for correlation
to antigen burden and prior mycobacterial sensitization.
Further studies are warranted.
6. Global Strategies for Discovery:
Gene Expression Profiling
One argument for use of rodent models in human tu-
berculosis research was the widespread availability of re-
agents to detect cytokines, chemokines, and for differ-
entiation of immune cells. The advent of functional
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genomics, proteomics, and completion of the bovine genome
sequence have dramatically improved our ability to study
immunopathogenesis of TB in cattle. In addition, there has
been a steady increase in numbers of antibody reagents
either prepared directly against bovine proteins or validated
for cross-reactivity against bovine orthologues. To date,
functional genomics studies of M. bovis infection in cattle
have been concentrated in twomain areas: (1) in vitro studies
aimed at defining changes in macrophage gene expression
profiles following infection with variousM. bovis isolates and
(2) ex-vivo studies to define a “gene expression signature”
that could be used to detect M. bovis-infected cattle. Many
of these studies have relied upon early renditions of cDNA
microarrays focused on bovine genes encoding proteins
known to be important in immunity [97–100].
Wedlock et al. compared gene expression patterns in
primary bovine alveolar macrophages infected with a viru-
lent M. bovis strain and its attenuated isogenic counterpart
[101]. This study employed a cDNA microarray containing
over 20,000 bovine-expressed sequence tags (ESTs) as well as
amplicons representing various bovine and cervine cytokines
[102]. While virulent and attenuatedM. bovis isolates grew at
comparable rates in the alveolarmacrophages, initial analyses
suggested that as many as 45% of the ESTs were diﬀerentially
expressed between the two infection groups [101]. Of
the 20 most diﬀerentially expressed genes, IL-8, mono-
cyte chemotactant protein (MCP)-1 (CCL2), epithelial cell
inflammatory protein-1, Groα (CXCL1), CDC-like kinase
3, and fibrinogen-like protein-2 were prominent. Wedlock
et al. concluded that alveolar macrophages infected with
virulent M. bovis adopted a much more proinflammatory
gene expression profile than similar cells infected with
the attenuated isogenic strain [101]. Another study using
microarray technology found that lower levels of chemokines
were expressed by M. bovis-infected alveolar macrophages
thanM. tuberculosis-infected cells, highlighted by the authors
as a potential mechanism by which M. bovis can circumvent
activation of the host chemotactic response and evade killing
[103]. Of note, there appears to be species diﬀerences in the
response of macrophages to M. bovis as human monocytes
and monocyte-derived macrophages (MDM cells) infected
with M. bovis do not produce significant IL-8 [104]. In
addition, human cells infected with virulent M. tuberculosis
produce large amounts of IL-10 [104], which was not
observed in M. bovis-infected alveolar macrophages. How-
ever, as acknowledged by the authors, it remains a possibility
that these discrepancies are due to diﬀerences betweenMDM
cells and primary alveolar macrophages rather than actual
species diﬀerences. Experiments to refine these observations
have not been reported to date.
Meade et al. conducted a series of studies aimed at defin-
ing the gene expression profiles of bovine peripheral blood
mononuclear cells (PBMCs) from M. bovis-infected cattle
following stimulation with antigens of M. bovis (PPD-B)
in vitro [99]. Samples were collected throughout a
24 hour time course of stimulation. Comparisons were made
primarily between PPD-B-stimulated and -unstimulated
PBMC mRNA profiles. This study utilized a bovine-specific
cDNA microarray (BOTL-4) designed primarily for immune
studies in cattle and containing over 1300 ESTs and ampli-
cons spotted in triplicate [105, 106]. Statistical analysis
revealed that of the >1300 genes present on the BOTL-4
microarray, 224 (∼17%) were diﬀerentially expressed in
PPD-B-stimulated PBMCs when compared to unstimulated
PBMCs from the same chronically infected animals [99].
Major ontological classes of genes that showed significant
diﬀerential expression included those encoding proteins
involved in metabolism, cell communication, response to
biotic stimulus, death, and development. Molecular func-
tions most aﬀected by stimulation were catalytic activity,
protein binding, and nucleic acid binding. During the 24-
hour stimulation time course, the authors observed a cyclical
gene expression pattern with larger numbers of transcripts
diﬀerentially expressed at 3-hour and 12-hour post stimula-
tion relative to 6-hour and 24-hour time points. Although
this could be related to cyclical receptor signalling, the fact
that very few transcripts were commonly aﬀected throughout
the time course suggests that it is due to activation of early
response transcripts followed by a lag (possibly due to tran-
scription/translation of early response transcripts) followed
by a secondary wave of gene expression. Alternatively, this
pattern could be due to immediate response to mycobacterial
antigens through, for example, Toll-like receptor signalling
followed by a secondary stimulation after uptake, processing,
and antigen presentation. The authors suggested that this
early response patternmight represent a signature ofM. bovis
infection [99].
In a series of subsequent studies, Meade et al. pursued
the idea that a unique and rapid gene expression pattern in
PBMCs could be used to reliably detect M. bovis-infected
cattle [107, 108]. Biomarker discovery using genomics
and proteomics has been applied to infections with other
pathogens in several host species, including humans and
cattle [109–112]. Meade et al. demonstrated that total
leukocytes from late-stage M. bovis-infected cattle contained
more lymphocytes (72%) than similar samples from control
healthy cattle (43%) and that healthy controls contained
more neutrophils (40%) than cells from late-stage M. bovis-
infected cattle (14%) [113]. Given such diﬀerences, one
would expect that total leukocyte gene expression profiles
from late-stage M. bovis-infected cattle would be diﬀerent
than those from healthy controls. Indeed, of the >1,300 genes
represented on the BOTL-5 microarray, 378 (27%) showed
significant diﬀerential expression (P < .05) between total
leukocytes from healthy and infected cattle. Importantly, the
suppression of innate immune gene expression detected in
chronically infected animals [113] could be one mechanism
by which M. bovis infection persists [31], and current diag-
nostics fail to identify all infected animals. Of importance,
application of a hierarchical clustering algorithm identified
a subset of 15 genes whose combined expression pattern
appeared to be indicative of infection status [99]. It may also
be the case that the early and transient profile of diﬀerential
gene expression detected in these studies, could shed light
on the mechanisms and kinetics of the shift in the immune
system toward a nonprotective, antibody-mediated response
associated with progression to chronic disease [31, 47]. It
is also possible that expression patterns of this gene subset
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could be used to diagnose M. bovis infection in cattle.
Unfortunately, this was not rigorously tested using a blinded
set of samples in the present study. However a recent review
from this group suggests that work in this area is on-going
[114]. It waits to be seen if changes in expression of such a
gene subset are specific toM. bovis infection or are a common
response to bacterial invasion.
In order to address the issue of an M. bovis specific gene
expression pattern, Meade et al. performed another time
course study using M. bovis antigen stimulation to elicit
changes in gene expression that would not necessarily be
common with any other bacterial infection [107, 108]. This
study revealed a subset of 18 genes that showed opposite
expression changes (up- or downregulated) in cells from
healthy control cattle and M. bovis-infected cattle. In keeping
with previous results and relevant literature, the nature of the
diﬀerentially expressed genes suggested a significant role for
Toll-like receptor signalling in response to M. bovis antigens
[107, 108, 113, 114]. This is postulated to have significant
consequences for the development of disease in humans
[115], and the same may hold true in cattle.
While there may be some species diﬀerences between the
response of humans and cattle to mycobacterial infections, as
discussed elsewhere in this article, there are fewer significant
diﬀerences between cattle and humans than between mice
and humans. This can have significant advantages for
translational understanding of the mechanisms of patho-
genesis [116]. Detailed pan-genomic transcriptomic analyses
will also aid the understanding and potential therapeutic
targeting of M. bovis infections in other natural infection
models, including wildlife species that pose threats as
reservoirs of infection [117–119]. Significant progress has
been made in defining a gene expression signature that may
be diagnostic for M. bovis infection in cattle. In many cases,
eradication of M. bovis is diﬃcult because currently used
diagnostic tests do not detect all infected cattle. Development
of an improved test, based on genomic or proteomic
biomarkers, would be a great improvement. Particular focus
also needs to be paid to the development of early stage
indicators of infection in order to minimize the losses
and risks associated with advanced or chronic infection.
Evidence for diﬀerential cytokine gene expression, found
to be associated with pathology in M. bovis infected cattle
[120], and a pre-existing gene expression profile in infected
animals holds promise for such a resolution [108, 113].
In fact a recent study has made considerable progress in
this area using comparative proteomic analysis to identify
biomarkers of subclinical (latent) M. bovis infection [121].
Serum levels from experimentally infected animals showed
marked increases of alpha-1-microglobulin/bikunin precur-
sor (AMBP) protein, alpha-1-acid glycoprotein, alpha-1-
microglobulin and fetulin proteins in M. bovis infected
animals, which were absent from animals challenged with
other closely related mycobacteria. As yet, genomic and
proteomic tests have not been subjected to rigorous field
testing, presumably because funding sources for a large
blinded study have not been available. In addition, transfer
of genomics information from M. bovis infected cattle to
M. tuberculosis (and M. bovis) infections in humans has
not been forthcoming. However, functional genomics has
added new dimensions to our understanding of the bovine
immune response to M. bovis infection, and the advent
of new technologies including next-generation sequencing
holds significant potential for the development of novel
intervention strategies against this recalcitrant disease.
7. Summary
The advent of genomic resources for cattle has dramat-
ically improved our ability to use this species in studies
of immunity to a variety of diseases, including zoonotic
infections such as M. bovis. Although the mouse model has
proven useful in comparative studies of tuberculosis, recent
advances in the characterization of the immune system of
cattle now aﬀord an opportunity to gain further insight
into the mechanisms of immunopathogenesis utilizing a
natural host/pathogen relationship. It is clear from recent
investigations that the Th1/Th2 paradigm must be expanded
to include the newly identified CD4 and CD8 T cells subsets
that comprise the eﬀector and regulatory subsets responding
to mycobacterial antigens during diﬀerent stages of infec-
tion. Further studies are needed to determine the relative
contribution of Treg and Th17 subsets in the response of
cattle to M. bovis infection/vaccination. Eﬀorts to elucidate
diﬀerences between the immune response profile of indi-
viduals with latent infection and patients with progressive
disease suggest that latency is associated with maintenance
of subsets of CD4 T cells [117]. The calf TB model aﬀords
a unique opportunity for evaluation of neonatal immune
responses to vaccination/infection. Promising TB vaccines
may also be evaluated in the calf (safety and eﬃcacy) prior
to testing in costly NHPs (thereby prioritizing candidates),
and as presented in this review, important mechanisms of
immunity may be uncovered by the use of the calf for the
study of TB.
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